A story in the Oct. 1, 2004, issue of BioWorld Today should have said that the FDA issued an approvable letter in May for Vicuron Pharmaceuticals Inc.'s anidulafungin, indicating that the company could achieve approval upon completion of an ongoing Phase III trial to treat invasive candidiasis/candidemia or the completion of further clinical work in patients with candidal disease refractory to other treatments.

Editor's Note: The change has been made in BioWorld Online.

No Comments